公开(公告)号：US07282126B2

公开(公告)日：2007-10-16

申请号：US10617750

申请日：2003-07-14

Applicant: Zhaowei Liu ,  Zhiyong Guo ,  Christina Maye ,  Kevin R. Gutshall

Inventor： Zhaowei Liu ,  Zhiyong Guo ,  Christina Maye ,  Kevin R. Gutshall

IPC: G01N27/453

CPC classification number: G01N27/44773 ,  C12Q1/6816 ,  C12Q1/6827 ,  C12Q2600/156 ,  G01N27/44704 ,  G01N27/44721 ,  C12Q2565/125 ,  C12Q2545/113 ,  C12Q2527/101 ,  C12Q2565/131 ,  C12Q2527/107

Abstract: The present invention relates to a method of determining the genotype of a sample polynucleotide having at least a first variant site. At least a portion of the sample polynucleotide is amplified to obtain first amplicons, the first amplicons including the first variant site. The first amplicons are combined with first and second different polynucleotide controls, the first and second polynucleotide controls differing by at least one base therealong, the position of the at least one differing base corresponding to the first variant site of the sample polynucleotide. A plurality of first duplexes are prepared, each of at least some of the first duplexes comprising (i) a polynucleotide strand of one of the first amplicons and (ii) a complementary polynucleotide strand of the first polynucleotide control. A plurality of second duplexes are prepared, each of at least some of the second duplexes comprising (i) a polynucleotide strand of one of the first amplicons and (ii) a complementary polynucleotide strand of the second polynucleotide control. The first and second duplexes are subjected to temperature gradient electrophoresis (TGE) to obtain first and second electrophoresis data. The genotype of the first variant site of the sample polynucleotide is determiend based on the first and second electrophoresis data.

Abstract translation: 本发明涉及确定具有至少第一变异位点的样品多核苷酸的基因型的方法。 扩增样品多核苷酸的至少一部分以获得第一扩增子，第一扩增子包括第一变体位点。 将第一扩增子与第一和第二不同多核苷酸对照组合，第一和第二多核苷酸对照与其中至少一个碱基不同，所述至少一个不同碱基对应于样品多核苷酸的第一个变异位点的位置。 制备多个第一双链体，至少一些第一双链体包含（i）第一扩增子之一的多核苷酸链和（ii）第一多核苷酸对照的互补多核苷酸链。 制备多个第二双链体，至少一些第二双链体包含（i）第一扩增子之一的多核苷酸链和（ii）第二多核苷酸对照的互补多核苷酸链。 对第一和​​第二双链体进行温度梯度电泳（TGE）以获得第一和第二电泳数据。 基于第一和第二电泳数据确定样品多核苷酸的第一变体位点的基因型。

公开(公告)号：US20050064400A1

公开(公告)日：2005-03-24

申请号：US10287808

申请日：2002-11-05

Applicant: Zhiyong Guo ,  Zhaowei Liu ,  Qingbo Li

Inventor： Zhiyong Guo ,  Zhaowei Liu ,  Qingbo Li

IPC: C12Q1/68 ,  C12Q1/6827 ,  G01N33/48 ,  G01N33/50 ,  G06F19/00

CPC classification number: C12Q1/6827 ,  C12Q2565/125 ,  C12Q2527/101

Abstract: The present invention relates to a method for determining the presence of a mutation in a first sample comprising first polynucleotides. The reference sample comprises reference polynucleotides. The first sample and a reference sample are subjected to electrophoresis in the presence of at least one intercalating dye. During electrophoresis the temperature of the first sample and the reference sample is changed by an amount sufficient to change an electrophoretic mobility of at least one of the first or reference polynucleotides. Fluorescence intensity data are obtained. The fluorescence intensity data are indicative of the presence of the first and reference polynucleotides. The data are processed to determine the presence of mutation in the first polynucleotides.

Abstract translation: 本发明涉及一种用于确定包含第一多核苷酸的第一样品中突变存在的方法。 参考样品包括参考多核苷酸。 第一个样品和参考样品在至少一个插层染料存在下进行电泳。 在电泳期间，第一样品和参考样品的温度改变足以改变至少一个第一或参考多核苷酸的电泳迁移率的量。 获得荧光强度数据。 荧光强度数据表明第一和参考多核苷酸的存在。 处理数据以确定第一多核苷酸中突变的存在。

公开(公告)号：US20140194639A1

公开(公告)日：2014-07-10

申请号：US13984724

申请日：2012-02-15

Applicant: Banglin Chen ,  Zhiyong Guo

Inventor： Banglin Chen ,  Zhiyong Guo

IPC: C10L3/00

CPC classification number: C10L3/003 ,  B01J20/226 ,  C07C63/331 ,  C07F1/08 ,  C10L3/10 ,  F17C11/005 ,  F17C11/007

Abstract: A 3D porous metal-organic framework and method of making are described. In some embodiments, a 3D porous metal-organic framework may be based on a trinodal (3,3,4) net of zyg topology by the self-assembly of the nonlinear hexacarboxylate (BHB) with the paddle-wheel Cu2(COO)4 cluster. Although its porosity and surface area are moderate, the open copper sites and optimal pore spaces enable the pore spaces to be fully utilized for methane storage, resulting in a high methane storage density and high absolute volumetric methane storage at room temperature and 35 bar. By the immobilization of high density open metal sites and the deliberate control of the pore space for their efficient methane storage, this porous MOF functions as an efficient media for methane and natural gas storage.

Abstract translation: 描述了3D多孔金属 - 有机骨架和制造方法。 在一些实施方案中，三维多孔金属 - 有机骨架可以通过非线性六羧酸盐（BHB）与桨轮Cu2（COO）4的自组装基于三点（3,3,4）网状结构网 簇。 尽管其孔隙度和表面积适中，开放的铜位点和最佳的孔隙空间使得孔隙空间能够充分利用于甲烷储存，从而在室温和35巴下产生较高的甲烷储存密度和高绝对体积的甲烷储存。 通过固定高密度开放金属部位和有效控制孔隙空间以实现有效的甲烷储存，该多孔MOF作为甲烷和天然气储存的有效介质。

公开(公告)号：US08133724B2

公开(公告)日：2012-03-13

申请号：US12562031

申请日：2009-09-17

Applicant: Yun Qiu ,  Zhiyong Guo ,  Xi Yang

Inventor： Yun Qiu ,  Zhiyong Guo ,  Xi Yang

IPC: C07K14/72 ,  C12N5/10 ,  C12N15/12

CPC classification number: C07K14/721 ,  C12N15/1138 ,  C12N2310/14

Abstract: The present invention relates to novel androgen receptor splice variants (AR3, AR4, AR4b, AR5 and AR8) and variants and fragments thereof which have a role in the progression of androgen independent prostate cancer. The invention further relates to compositions and methods which can be used to identify and treat prostate cancer based on these novel androgen receptor splice variants, as well as methods for screening agents which modulate the activity and/or expression of the androgen receptor splice variants. Vectors, host cells and recombinant methods for producing the same and transgenic animals are also provided.

Abstract translation: 本发明涉及在雄激素非依赖性前列腺癌进展中具有作用的新型雄激素受体剪接变体（AR3，AR4，AR4b，AR5和AR8）及其变体和片段。 本发明还涉及可用于鉴定和治疗基于这些新型雄激素受体剪接变体的前列腺癌的组合物和方法，以及用于筛选调节雄激素受体剪接变体的活性和/或表达的试剂的方法。 还提供载体，宿主细胞和用于产生相同和转基因动物的重组方法。

公开(公告)号：US20100068802A1

公开(公告)日：2010-03-18

申请号：US12562031

申请日：2009-09-17

Applicant: Yun Qiu ,  Zhiyong Guo ,  Xi Yang

Inventor： Yun Qiu ,  Zhiyong Guo ,  Xi Yang

IPC: C12N5/00 ,  C07H21/00 ,  C07K2/00

CPC classification number: C07K14/721 ,  C12N15/1138 ,  C12N2310/14

Abstract: The present invention relates to novel androgen receptor splice variants (AR3, AR4, AR4b, AR5 and AR8) and variants and fragments thereof which have a role in the progression of androgen independent prostate cancer. The invention further relates to compositions and methods which can be used to identify and treat prostate cancer based on these novel androgen receptor splice variants, as well as methods for screening agents which modulate the activity and/or expression of the androgen receptor splice variants. Vectors, host cells and recombinant methods for producing the same and transgenic animals are also provided.

Abstract translation: 本发明涉及在雄激素非依赖性前列腺癌进展中具有作用的新型雄激素受体剪接变体（AR3，AR4，AR4b，AR5和AR8）及其变体和片段。 本发明还涉及可用于鉴定和治疗基于这些新型雄激素受体剪接变体的前列腺癌的组合物和方法，以及用于筛选调节雄激素受体剪接变体的活性和/或表达的试剂的方法。 还提供载体，宿主细胞和用于产生相同和转基因动物的重组方法。

公开(公告)号：US07175750B2

公开(公告)日：2007-02-13

申请号：US10287826

申请日：2002-11-05

Applicant: Zhiyong Guo ,  Zhaowei Liu ,  Qingbo Li

Inventor： Zhiyong Guo ,  Zhaowei Liu ,  Qingbo Li

IPC: G01N27/447

CPC classification number: G01N27/44773 ,  C12Q1/6816 ,  C12Q1/6827 ,  C12Q2600/156 ,  G01N27/44704 ,  G01N27/44721 ,  C12Q2565/125 ,  C12Q2545/113 ,  C12Q2527/101 ,  C12Q2565/131 ,  C12Q2527/107

Abstract: The present invention relates to a method for determining the presence of a mutation in a first sample comprising first nucleotides. The reference sample comprising reference nucleotides. The first sample and a reference sample are subjected to electrophoresis in the presence of at least one intercalating dye. During electrophoresis the temperature of the first sample and the reference sample is changed by an amount sufficient to change an electrophoretic mobility of at least one of the first or reference nucleotides. Fluorescence intensity data are obtained. The fluorescence intensity data are indicative of the presence of the first and reference nucleotides. At least one of the first sample or reference samples comprises products resulting from a polymerase chain reaction (PCR), the products not having been desalted prior to electrophoresis.

Abstract translation: 本发明涉及用于确定包含第一核苷酸的第一样品中突变的存在的方法。 参考样品包含参考核苷酸。 第一个样品和参考样品在至少一个插层染料存在下进行电泳。 在电泳期间，第一样品和参考样品的温度改变足以改变至少一个第一个或参考核苷酸的电泳迁移率的量。 获得荧光强度数据。 荧光强度数据表明第一个和参考核苷酸的存在。 第一个样本或参考样本中的至少一个包含由聚合酶链反应（PCR）产生的产物，该产物在电泳之前未脱盐。

公开(公告)号：US09376641B2

公开(公告)日：2016-06-28

申请号：US13984724

申请日：2012-02-15

Applicant: Banglin Chen ,  Zhiyong Guo

Inventor： Banglin Chen ,  Zhiyong Guo

IPC: C07F1/08 ,  C10L3/00 ,  B01J20/22 ,  C07C63/331 ,  F17C11/00 ,  C10L3/10

CPC classification number: C10L3/003 ,  B01J20/226 ,  C07C63/331 ,  C07F1/08 ,  C10L3/10 ,  F17C11/005 ,  F17C11/007

Abstract: A 3D porous metal-organic framework and method of making are described. In some embodiments, a 3D porous metal-organic framework may be based on a trinodal (3,3,4) net of zyg topology by the self-assembly of the nonlinear hexacarboxylate (BHB) with the paddle-wheel Cu2(COO)4 cluster. Although its porosity and surface area are moderate, the open copper sites and optimal pore spaces enable the pore spaces to be fully utilized for methane storage, resulting in a high methane storage density and high absolute volumetric methane storage at room temperature and 35 bar. By the immobilization of high density open metal sites and the deliberate control of the pore space for their efficient methane storage, this porous MOF functions as an efficient media for methane and natural gas storage.

Abstract translation: 描述了3D多孔金属 - 有机骨架和制造方法。 在一些实施方案中，三维多孔金属 - 有机骨架可以通过非线性六羧酸盐（BHB）与桨轮Cu2（COO）4的自组装基于三点（3,3,4）网状结构网 簇。 尽管其孔隙度和表面积适中，开放的铜位点和最佳的孔隙空间使得孔隙空间能够充分利用于甲烷储存，从而在室温和35巴下产生较高的甲烷储存密度和高绝对体积的甲烷储存。 通过固定高密度开放金属部位和有效控制孔隙空间以实现有效的甲烷储存，该多孔MOF作为甲烷和天然气储存的有效介质。

公开(公告)号：US08841422B2

公开(公告)日：2014-09-23

申请号：US13403029

申请日：2012-02-23

Applicant: Yun Qiu ,  Zhiyong Guo ,  Xi Yang

Inventor： Yun Qiu ,  Zhiyong Guo ,  Xi Yang

IPC: C07K16/28 ,  C07K16/30 ,  C12N15/113 ,  C07K14/72

CPC classification number: C07K14/721 ,  C12N15/1138 ,  C12N2310/14

Abstract: The present invention relates to novel androgen receptor splice variants (AR3, AR4, AR4b, AR5 and AR8) and variants and fragments thereof which have a role in the progression of androgen independent prostate cancer. The invention further relates to compositions and methods which can be used to identify and treat prostate cancer based on these novel androgen receptor splice variants, as well as methods for screening agents which modulate the activity and/or expression of the androgen receptor splice variants. Vectors, host cells and recombinant methods for producing the same and transgenic animals are also provided.

Abstract translation: 本发明涉及在雄激素非依赖性前列腺癌进展中具有作用的新型雄激素受体剪接变体（AR3，AR4，AR4b，AR5和AR8）及其变体和片段。 本发明还涉及可用于鉴定和治疗基于这些新型雄激素受体剪接变体的前列腺癌的组合物和方法，以及用于筛选调节雄激素受体剪接变体的活性和/或表达的试剂的方法。 还提供载体，宿主细胞和用于产生相同和转基因动物的重组方法。

公开(公告)号：US20120156770A1

公开(公告)日：2012-06-21

申请号：US13403029

申请日：2012-02-23

Applicant: Yun Qiu ,  Zhiyong Guo ,  Xi Yang

Inventor： Yun Qiu ,  Zhiyong Guo ,  Xi Yang

IPC: C07K14/705 ,  C12N15/63 ,  C07K16/28 ,  C12N5/10 ,  C12N1/21 ,  C12N1/15 ,  C12N1/19 ,  C12N15/12 ,  C07K16/46

CPC classification number: C07K14/721 ,  C12N15/1138 ,  C12N2310/14

Abstract: The present invention relates to novel androgen receptor splice variants (AR3, AR4, AR4b, AR5 and AR8) and variants and fragments thereof which have a role in the progression of androgen independent prostate cancer. The invention further relates to compositions and methods which can be used to identify and treat prostate cancer based on these novel androgen receptor splice variants, as well as methods for screening agents which modulate the activity and/or expression of the androgen receptor splice variants. Vectors, host cells and recombinant methods for producing the same and transgenic animals are also provided.

Abstract translation: 本发明涉及在雄激素非依赖性前列腺癌进展中具有作用的新型雄激素受体剪接变体（AR3，AR4，AR4b，AR5和AR8）及其变体和片段。 本发明还涉及可用于鉴定和治疗基于这些新型雄激素受体剪接变体的前列腺癌的组合物和方法，以及用于筛选调节雄激素受体剪接变体的活性和/或表达的试剂的方法。 还提供载体，宿主细胞和用于产生相同和转基因动物的重组方法。